ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

OBX vs KURA // OPERATING MARGIN

Obsidian Therapeutics Inc. (NASDAQ) VS. Kura Oncology Inc. (NASDAQ) • 15-METRIC TALLY: OBX 3 — KURA 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OBX VS. KURA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC OBX KURA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -10.09% -7.53% -2.56 KURA /fcf-yield <GO>
Operating Margin ACTIVE — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 25.20% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 26.00 0.20 +25.80 OBX /balance-sheet <GO>
Piotroski F-Score Quality 2/9 4/9 -2.00 KURA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 55.3 48.9 +6.40 OBX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $913.6M $912.7M $884.9K OBX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR OBX REV KURA REV OBX GROSS % KURA GROSS % OBX FCF KURA FCF
FY 2025 $295.9M $67.5M — — -$90.5M -$70.7M
FY 2024 $255.5M $53.9M — — -$75.8M $133.8M
FY 2023 — $464.3M — — — -$124.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OBX // BETA —
KURA // BETA —